COMPASS Pathways (5Y6) Stock Forecast & Price Target

Compare

4 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

5Y6 Analyst Ratings

Strong Buy

10 Buy

1 Hold

0 Sell

Based on 11 analysts giving stock ratings to

COMPASS

Pathways

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

5Y6 Stock 12 Month Forecast

Average Price Target

€19.10

▲(278.26% Upside)

Based on 11 Wall Street analysts offering 12 month price targets for COMPASS Pathways in the last 3 months. The average price target is €19.10 with a high forecast of €60.53 and a low forecast of €6.92. The average price target represents a 278.26% change from the last price of €5.05.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"€1","16":"€16","31":"€31","46":"€46","61":"€61"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":60.528971299999995,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€60.53</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19.10200003363636,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€19.10</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.91759672,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€6.92</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,16,31,46,61],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.6,9.825305484615384,14.050610969230767,18.27591645384615,22.501221938461534,26.726527423076917,30.951832907692307,35.17713839230769,39.40244387692307,43.627749361538456,47.85305484615384,52.07836033076922,56.30366581538461,{"y":60.528971299999995,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.6,6.638615387202797,7.677230774405594,8.71584616160839,9.754461548811188,10.793076936013986,11.831692323216782,12.870307710419578,13.908923097622376,14.947538484825172,15.98615387202797,17.024769259230766,18.063384646433562,{"y":19.10200003363636,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.6,5.701353593846154,5.802707187692308,5.904060781538461,6.005414375384615,6.106767969230769,6.208121563076923,6.309475156923076,6.41082875076923,6.512182344615384,6.613535938461538,6.7148895323076925,6.816243126153846,{"y":6.91759672,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.94,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.62,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.12,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.5,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.36,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.62,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.74,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.779,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.45,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.6,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.6,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.45,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.6,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€60.53

Average Price Target€19.10

Lowest Price Target€6.92

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Ritu Baral

TD Cowen

€25.08

Buy

396.56%

Upside

Reiterated

03/19/26

Analysts Conflicted on These Healthcare Names: Whitehawk Therapeutics (NASDAQ: WHWK), COMPASS Pathways (NASDAQ: CMPS) and Relmada Therapeutics (NASDAQ: RLMD)

Patrick Trucchio

H.C. Wainwright

€60.53

Buy

1098.59%

Upside

Reiterated

03/04/26

H.C. Wainwright Remains a Buy on COMPASS Pathways (CMPS)

Michael Okunewitch

Maxim Group

€10.38

Buy

105.47%

Upside

Reiterated

02/24/26

Analysts Are Bullish on Top Healthcare Stocks: Geron (GERN), COMPASS Pathways (CMPS)

Vikram Purohit

Morgan Stanley

€9.51→€15.56

Buy

208.21%

Upside

Reiterated

02/18/26

Compass Pathways price target raised to $18 from $11 at Morgan StanleyCompass Pathways price target raised to $18 from $11 at Morgan Stanley

Leonid Timashev

RBC Capital

€18.16→€19.02

Buy

276.70%

Upside

Reiterated

02/17/26

RBC Capital Keeps Their Buy Rating on COMPASS Pathways (CMPS)

Sumant Kulkarni

Canaccord Genuity

€12.97→€17.29

Buy

242.46%

Upside

Reiterated

02/17/26

Canaccord Genuity Sticks to Its Buy Rating for COMPASS Pathways (CMPS)

Thomas Shrader

BTIG

€12.11

Buy

139.72%

Upside

Reiterated

02/17/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Francois Brisebois

LifeSci Capital

€12.97→€16.43

Buy

225.33%

Upside

Reiterated

02/17/26

Analysts Conflicted on These Healthcare Names: Sensus Healthcare (NASDAQ: SRTS), NeoGenomics (NASDAQ: NEO) and COMPASS Pathways (NASDAQ: CMPS)

Gavin Clark-Gartner

Evercore ISI

€6.92

Hold

36.98%

Upside

Reiterated

02/06/26

COMPASS Pathways (CMPS) Gets a Hold from Evercore ISI

Paul Matteis

Stifel Nicolaus

€9.51

Buy

88.35%

Upside

Reiterated

01/08/26

Stifel Nicolaus Remains a Buy on COMPASS Pathways (CMPS)

Joshua Schimmer

Cantor Fitzgerald

€17.29

Buy

242.46%

Upside

Reiterated

01/07/26

Cantor Fitzgerald Sticks to Its Buy Rating for COMPASS Pathways (CMPS)

Jay Olson

Oppenheimer

€12.97

Buy

156.84%

Upside

Initiated

12/10/25

Compass Pathways upgraded to Outperform from Perform at OppenheimerCompass Pathways upgraded to Outperform from Perform at Oppenheimer

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Ritu Baral

TD Cowen

€25.08

Buy

396.56%

Upside

Reiterated

03/19/26

Analysts Conflicted on These Healthcare Names: Whitehawk Therapeutics (NASDAQ: WHWK), COMPASS Pathways (NASDAQ: CMPS) and Relmada Therapeutics (NASDAQ: RLMD)

Patrick Trucchio

H.C. Wainwright

€60.53

Buy

1098.59%

Upside

Reiterated

03/04/26

H.C. Wainwright Remains a Buy on COMPASS Pathways (CMPS)

Michael Okunewitch

Maxim Group

€10.38

Buy

105.47%

Upside

Reiterated

02/24/26

Analysts Are Bullish on Top Healthcare Stocks: Geron (GERN), COMPASS Pathways (CMPS)

Vikram Purohit

Morgan Stanley

€9.51→€15.56

Buy

208.21%

Upside

Reiterated

02/18/26

Compass Pathways price target raised to $18 from $11 at Morgan StanleyCompass Pathways price target raised to $18 from $11 at Morgan Stanley

Leonid Timashev

RBC Capital

€18.16→€19.02

Buy

276.70%

Upside

Reiterated

02/17/26

RBC Capital Keeps Their Buy Rating on COMPASS Pathways (CMPS)

Sumant Kulkarni

Canaccord Genuity

€12.97→€17.29

Buy

242.46%

Upside

Reiterated

02/17/26

Canaccord Genuity Sticks to Its Buy Rating for COMPASS Pathways (CMPS)

Thomas Shrader

BTIG

€12.11

Buy

139.72%

Upside

Reiterated

02/17/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Francois Brisebois

LifeSci Capital

€12.97→€16.43

Buy

225.33%

Upside

Reiterated

02/17/26

Analysts Conflicted on These Healthcare Names: Sensus Healthcare (NASDAQ: SRTS), NeoGenomics (NASDAQ: NEO) and COMPASS Pathways (NASDAQ: CMPS)

Gavin Clark-Gartner

Evercore ISI

€6.92

Hold

36.98%

Upside

Reiterated

02/06/26

COMPASS Pathways (CMPS) Gets a Hold from Evercore ISI

Paul Matteis

Stifel Nicolaus

€9.51

Buy

88.35%

Upside

Reiterated

01/08/26

Stifel Nicolaus Remains a Buy on COMPASS Pathways (CMPS)

Joshua Schimmer

Cantor Fitzgerald

€17.29

Buy

242.46%

Upside

Reiterated

01/07/26

Cantor Fitzgerald Sticks to Its Buy Rating for COMPASS Pathways (CMPS)

Jay Olson

Oppenheimer

€12.97

Buy

156.84%

Upside

Initiated

12/10/25

Compass Pathways upgraded to Outperform from Perform at OppenheimerCompass Pathways upgraded to Outperform from Perform at Oppenheimer

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering COMPASS Pathways

3 Months

xxx

Success Rate

5/9 ratings generated profit

Average Return

+13.81%

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 55.56% of your transactions generating a profit, with an average return of +13.81% per trade.

1 Year

Michael OkunewitchMaxim Group

Success Rate

6/9 ratings generated profit

Average Return

+28.91%

Copying Michael Okunewitch's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +28.91% per trade.

2 Years

xxx

Success Rate

6/9 ratings generated profit

Average Return

+34.61%

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of +34.61% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

5Y6 Analyst Recommendation Trends

Rating

Nov 25

Dec 25

Jan 26

Feb 26

Mar 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 5Y6 has received 19 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. 5Y6 average Analyst price target in the past 3 months is 19.10.

Each month's total comprises the sum of three months' worth of ratings.

5Y6 Financial Forecast

5Y6 Earnings Forecast

Currently, no earnings data available.

No data currently available

5Y6 Sales Forecast

Currently, no sales data available.

5Y6 Stock Forecast FAQ

What is DE:5Y6’s average 12-month price target, according to analysts?

Based on analyst ratings, COMPASS Pathways’s 12-month average price target is 19.10.

What is DE:5Y6’s upside potential, based on the analysts’ average price target?

COMPASS Pathways has 278.26% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is COMPASS Pathways a Buy, Sell or Hold?

COMPASS Pathways has a consensus rating of Strong Buy, which is based on 10 buy ratings, 1 hold ratings and 0 sell ratings.

What is COMPASS Pathways’s share price target?

The average share price target for COMPASS Pathways is 19.10. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €60.53 ,and the lowest forecast is €6.92. The average share price target represents 278.26% Increase from the current price of €5.05.

What do analysts say about COMPASS Pathways?

COMPASS Pathways’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Streets Analysts.

How can I buy shares of COMPASS Pathways?

To buy shares of DE:5Y6, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

COMPASS Pathways (5Y6) Stock Forecast & Price Target

5Y6 Analyst Ratings

5Y6 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering COMPASS Pathways

5Y6 Analyst Recommendation Trends

5Y6 Financial Forecast

5Y6 Earnings Forecast

5Y6 Sales Forecast

5Y6 Stock Forecast FAQ

Detailed List of Analyst Forecasts